Cutaneous T-Cell Lymphoma Recurrent Completed Phase 2 Trials for Avelumab (DB11945)

Also known as: T-Cell Lymphoma Relapsed / Recurrent T-Cell Lymphoma / Recurrent Cutaneous T-cell lymphoma / T-cell lymphoma recurrent / Relapsed T-Cell Lymphoma / T-cell lymphoma NOS recurrent

IndicationStatusPhase
DBCOND0136063 (Cutaneous T-Cell Lymphoma Recurrent)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03046953Avelumab in Relapsed and Refractory Peripheral T-cell LymphomaTreatment